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Abstract: Childhood cancer is the leading cause of death by disease among U.S. children 
between infancy and age 15. Despite successes in treating solid tumors such as Wilms 
tumor, disappointments in the outcomes of high-risk solid tumors like neuroblastoma have 
precipitated efforts towards the early and accurate detection of these malignancies. This 
review summarizes available solid tumor serum biomarkers with a special focus on 
mediastinal and abdominal cancers in children.  
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1. Introduction 
Survival rates for children with cancer have improved over the past decades [1,2]. Recent trends 
show that although survival rates for children with primarily leukemias and lymphomas have improved, 
5-year survival rates for pediatric solid tumors have not changed over the past 2 decades. The limited 
numbers of clinical trials on pediatric solid malignancies as well as difficulty in discriminating and 
diagnosing solid masses by using standard techniques have hindered progress in this area. Therefore, it 
is imperative to not only accurately determine the type of masses but also detect tumor recurrences.  
Serum tumor markers offer great promise in the management of children with solid malignancies 
and are integral to disease diagnosis and prediction of treatment response. These cancer biomarkers are 
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biologically measured substances that are expressed by malignant tissues, circulating tumor 
components, or generated by the host in response to the tumor, and constitutively serve as essential 
tools to aid clinicians in making diagnosis, staging, and risk assessments. The nonspecific property of 
some markers to be differentially expressed in other tissues limits their clinical use and hampers 
accurate diagnosis of disease information. Although there is a wide spectrum of pediatric solid tumors, 
this review discusses only current trends in the use of serum biomarkers for detection and evaluation of 
solid tumors in the chest and abdomen of children. 
2. Thoracic Tumors 
Mediastinal tumors are relatively common in infants and children and represent a heterogeneous 
group of asymptomatic or potentially life-threatening neoplastic lesions that may carry complex 
diagnostic and therapeutic dilemmas. In general, imaging with a chest radiograph (anterior-posterior 
and lateral projections) and a computed tomography (CT) scan gives anatomic guidance for primary 
tumor location and information on mass morphology, extent, and relation to surrounding structures. 
Depending on tumor location within 3 different mediastinal compartments (anterior, middle, and 
posterior), a differential diagnosis may be made along with information on age and clinical history. 
Anterior mediastinal tumors include germ cell tumors (GCTs), thymic-related, cystic hygromas, and 
lymphomas. Common masses in the middle mediastinum are lymphomas, bronchogenic cysts, and 
granulomatous disease. Posterior mediastinal masses are mainly neurogenic tumors and represent the 
most common tumors in the mediastinum [3].  
3. Abdominal Tumors 
Pediatric solid abdominal neoplasms encompass a wide spectrum of diseases ranging from lesions 
causing significant morbidity and mortality [advanced stage neuroblastoma (NB)] to conditions that 
can be corrected by surgery alone [favorable-stage Wilms tumor (WT)]. The physician needs to 
determine the nature of the mass in a timely, safe, and cost-effective manner. Likely abdominal 
malignancies diagnosed in children include NB, WT, hepatoblastoma (HB), lymphoma, soft tissue 
sarcomas, and GCTs. As for thoracic masses, diagnostic imaging plays a major role in the diagnosis 
and management of pediatric abdominal masses, local disease staging, identification of distant 
metastases, and monitoring response to therapy. However, imaging techniques cannot always 
accurately distinguish between benign and malignant masses and may be discrepant from histologic 
staging [4]. Table 1 summarizes these biomarkers. In the following sections, we describe serum 
markers available for pediatric solid tumors in the chest and abdomen. Int. J. Mol. Sci. 2012, 13  1128 
 
Table 1. Serum markers in pediatric solid tumors. 
Tumor Marker 
Clinically 
Available 
Primary Cancer 
Additional 
Associated 
Malignancies 
Benign 
Diseases/Conditions 
Normal Values 
AFP  Yes HB   
HCC  
Nonseminomatous 
GCT 
Stomach, lung 
colon, and pancreatic 
cancer 
Alcohol abuse 
Hepatitis 
Cirrhosis 
Biliary tract obstruction 
Hereditary persistence 
cord: 9100–190,000 ng/mL 
1 day: 7900–170,000 
7 days: 3500–74,000 
8–14 days: 1500–59,000 
15–21 days: 580–23,000 
22–28 days: 320–6300 
29–45 days: 30–5800 
46–60 days: 16–2000 
3 months (61–90 d): 6–1000 
4 months (91–120 d): 3–420 
5 months (121–150 d): 2–220 
6 months (151–180 d): 1–130 
7 months–2years (181–720 d): 
1–87 
>2 years: 1–15 
HCG  Yes Nonseminomatous 
GCT 
Gestational 
trophoblastic disease 
Neuroendocrine, 
bladder, kidney, lung, 
head, neck, 
gastrointestinal, cervix, 
uterus and vulva tumors, 
lymphoma, and 
leukemia 
Pregnancy 
Fetal Down syndrome 
Marijuana use 
Hypogonadism 
<5 mU/mL (male, non-pregnant 
female) 
  Int. J. Mol. Sci. 2012, 13  1129 
 
 
Table 1. Cont. 
Tumor Marker 
Clinically 
Available 
Primary Cancer 
Additional 
Associated 
Malignancies 
Benign 
Diseases/Conditions 
Normal Values 
LDH  Yes GCT 
NB 
Lymphoma 
Melanoma 
Small-cell lung cancer 
Ewing sarcoma 
Osteogenic sarcoma 
Hemolysis 
Renal failure 
Liver and muscle diseases 
0–3 days: 290–775 U/L 
4–9 days: 545-2000 U/L 
10 days–23 months: 180–430 
U/L 
2–11 years: 110–295 U/L 
12–17 years: 100–190 U/L 
>18 years: 105–210 U/L 
2M [5–7]  Yes  Lymphoma  Breast, prostate, lung, 
renal, gastrointestinal, 
nasopharyngeal cancers, 
and multiple myeloma 
Inflammatory bowel 
disease [8] 
Autoimmune diseases 
Acute viral infections[9] 
1.1-2.4 mg/L 
CA125  Yes Ovary 
Lymphoma 
Cervical and 
endometrial cancers, 
malignant ascites, renal 
cancer, non–small cell 
lung, breast, and 
stomach cancers, 
primary peritoneal 
carcinoma  
Benign breast or ovarian 
disease 
Endometriosis 
Pelvic inflammatory 
disease 
Chronic renal failure 
Hepatitis 
0–35 U/mL 
Nm23-H1  No  Hematologic  Thyroid and NB  Psoriasis[10]  0–80 ng/mL 
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Table 1. Cont. 
Tumor Marker 
Clinically 
Available 
Primary Cancer 
Additional 
Associated 
Malignancies 
Benign Diseases/Conditions Normal Values 
Catecholamines  Yes NB   
PCC 
MTC [11]  Not applicable  24-hour Urine catecholamines, 
fractionated, & VMA * 
Epinephrine, 24 hr Urine 
0–2 years: Not established 
3–8 years: 1–7 μg/24 h 
9–12 years: 8 or less μg /24 h 
13–17 years: 11 or less μg /24 h 
Adults: 2–24 μg /24 h 
 
Norepinephrine, 24 h Urine 
0–2 years: Not established 
3–8 years: 5–41 μg/24 h 
9–12 years: 5–50 μg/24 h 
13–17 years: 12–88 μg/24 h 
Adults: 15–100 μg/24 h 
 
Calculated Total (N+E) 
0–2 years: Not established 
3–8 years: 9–51 μg/24 h 
9–12 years: 9–71 μg/24 h 
13–17 years: 13–90 μg/24 h 
Adults: 26–121 μg/24 h 
Dopamine, 24 hr Urine 
0–2 years: Not established 
3–8 years: 80–378 μg /24 h 
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Table 1. Cont. 
Tumor Marker
Clinically 
Available 
Primary Cancer 
Additional 
Associated 
Malignancies 
Benign Diseases/Conditions  Normal Values 
         9–12  years:  51–474  μg /24 h 
13–17 years: 51–645 μg/24 h 
Adults: 52–480 μg/24 h 
 
VMA, 24 h Urine 
3–8 years: 2.3 mg or less 
9–12 years: 3.4 mg or less 
13–17 years: 3.9 mg or less 
Adults: 6.0 or less 
CgA  Yes NB 
PCC  
Neuroendocrine tumors 
Prostate, lung, breast, 
gastric, and colon cancers
Hepatic disease, renal failure, 
rheumatoid arthritis, atrophic 
gastritis 
0–95 ng/mL 
NSE   Yes NB   
PCC 
MTC 
Gastric or lung carcinoids  
Wilms tumor 
 Rhabdomyosarcoma 
Brain hypoxia after MI, stroke, 
subarachnoid hemorrhage, traumatic 
brain damage, Guillain–Barré 
syndrome, bacterial meningitis and 
encephalitis [12–18] 
0–5 nmol/mL 
Renin   Yes  Renal (Wilms, clear cell 
carcinoma, and mesoblastic 
nephroma) [19,20] 
Ovarian, lung, pancreatic, 
adrenal, and colon cancers
Bartter syndrome, solitary renal 
cyst, cirrhosis, nephrotic syndrome, 
dehydration 
Hypertension 
1.9 to 3.7 ng/mL/h 
Note: Abbreviations: AFP, α-feto protein; β2M, β2-microglobulin; CA125, carbohydrate antigen 125; CgA, chromogranin A; HCG, β-human chorionic 
gonadotropin; HCC, hepatocellular carcinoma; LDH, lactate dehydrogenase; MTC, medullary thyroid cancer; MI, myocardial infarction; NB, 
neuroblastoma; NSE, neuron specific enolase; Nm23-H1, nucleoside diphosphate kinase A; PCC, pheochromocytoma; VMA, vanillylmandelic acid; * 
Pediatric reference ranges for catecholamines. Due to stress, plasma catecholamine levels are generally unreliable in infants and small children; urinary 
catecholamine assays are more reliable. Int. J. Mol. Sci. 2012, 13  1132 
 
4. Serum Biomarkers in Thoracic and Abdominal Tumors 
4.1. Pediatric Germ Cell Tumors (GCTs) 
The exact incidence of pediatric GCTs is not precisely known as approximately 50% of GCTs are 
benign [pure mature teratoma which do not secrete α-fetoprotein (AFP) and β-human chorionic 
gonadotropin (β-hCG)] and go unreported. Malignant GCTs account for 3% of all childhood cancers. 
GCTs may develop from variations in normal differentiation (gonadal GCTs), aberrant migration 
(extragonadal GCTs), or their combination. Extragonadal GCTs occur at various midline locations 
(retroperitoneal, genital, or cranial), but most commonly affect the mediastinum and sacrococcygeal 
region. Morphologically, they are divided into seminomas and nonseminomatous GCTs (NSGCTs). 
Most NSGCTs display mixed histologies, such as embryonal, choriocarcinomas, teratomas, and yolk 
sac tumors (YSTs). Although predicting the biological behavior in GCTs can be confusing owing to 
other factors such as patient age, histologic subtype, anatomic site, and clinical stage, serum levels of 
alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase 
(LDH) are well validated in their utility as noninvasive diagnostic indicators of GCTs [21]. These 
markers are sensitive and specific parameters for primary diagnosis, staging, monitoring of therapeutic 
response and follow-up [22]. In infants and adolescents who do not have underlying hepatic disease, a 
significant elevation of serum AFP or ß-hCG indicates significant “secreting” components of YST or 
choriocarcinoma, respectively, and rules out pure mature teratoma or seminoma; though seminomas 
may secrete minimal hCG.  
4.1.1. Alpha-Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG), and Lactate  
Dehydrogenase (LDH) 
The complete characterization of AFP, ß-hCG, and LDH as biologic disease markers have been 
addressed by numerous reports over the past several decades [23–47]. As a result of the extensive 
history and volume of effort directed towards the in depth analysis of these three markers, the 
development of guidelines for the recommendations on appropriate uses for GCTs serum markers have 
been well established and are some of the most long-standing predictive biomarkers assays [48,49]. 
Tests evaluating the pattern of expression of these serum markers provides not only the standard 
evaluation in a suspected GCTs but also the type of mixed NSGCT, as illustrated in Table 1, they can 
be associated with a broad differential diagnosis and a host of other solid malignancies. The biological 
importance of these established markers has been reinforced by the International Germ Cell 
Classification Consensus (IGCCC) which divides adults into three groups: good, intermediate, and 
poor prognosis groups based on the presence of primary mediastinal tumor, non-pulmonary metastases, 
and level of tumors markers [22]. Nonetheless in the United States, pediatric GCTs have typically been 
divided into risk groups according to stage; grade III and IV tumors, regardless of site, have been 
considered as higher risk. An analysis by the Children’s Oncology Group (COG) compared the 
application of the adult IGCC System to pediatric malignant NSGCT. The authors sought to determine 
whether the tumor marker criteria developed in adults would be prognostic among pediatric patients 
and whether tumor marker data may be relevant in pediatric risk stratification. Results from this study Int. J. Mol. Sci. 2012, 13 1133 
 
 
showed both systems were able to stratify pediatric patients into two distinct risk groups (although the 
two systems are not highly concordant), were prognostic, and effective [50].  
4.2. Hepatoblastoma (HB) 
Liver malignancies account for slightly more than 1% of all pediatric
 tumors, with approximately 
100–150 new cases of liver
 tumors being diagnosed annually in the US [51]. Pediatric liver tumors 
include hepatoblastoma (HB), hepatocellular carcinoma (HCC), sarcomas, GCTs, and rhabdoid tumors. 
The pediatric embryonal tumor HB accounts for 66% of malignant hepatic neoplasms. 
We have previously detailed the role of raised serum AFP levels in a significant proportion of 
GCTs, AFP measurements also have important diagnostic implications in pediatric liver tumors, most 
notably HB and HCC [52]. Elevations of serum AFP also occur in non-malignant conditions such as 
mesenchymal hamartoma, viral and chronic active hepatitis, cirrhosis, ulcerative colitis, tyrosinemia, 
and in some immune-deficiency conditions [53]. Most patients with HB have extremely high serum 
levels of AFP [up to 100,000 ± 1,000,000 times the normal value (<10 ng/mL)], but approximately 
5%–10% of patients have unexpectedly low or even normal AFP values [52]. For HB, the 
measurement of serum AFP levels is a valuable diagnostic test, owing to the correlation between AFP 
level and disease activity. Serial determinations of AFP determine the effectiveness of therapy. The 
half-life of the protein in the circulation is between 4 and 9 days, and levels usually return to the 
normal range (<10 ng/mL) by 4 ± 6 weeks of complete resection [54,55]. The failure of serum AFP 
levels to return to normal after surgery is an indication of either incomplete tumor resection or 
metastases. The importance of considering infants’ ages while interpreting AFP levels should be 
underscored, as age-dependent changes in serum AFP levels occur. AFP is initially synthesized in the 
yolk sac and is subsequently made by hepatocytes and gastrointestinal mucosa during embryogenesis; 
it reaches its peak concentration at approximately 12–14 weeks of gestation; and then declines 
thereafter, reaching normal concentration at 8–12 months of age [56]. As a result, AFP serum levels 
are highly elevated in neonates, and premature infants can have very high levels of AFP, which is 
accepted as normal (term neonates: 41,687 l g/L, preterm infants: 158,125 l g/L) [57].  
Because an elevated level of AFP may not be a reliable diagnostic tumor marker in the neoinfantile 
age period, it has been reported that the origin of AFP is distinguishable by the measurement of a 
different isoform of AFP, known as the lectin fraction (AFP-L3). Recently, the usefulness of the   
AFP-L3 fraction was analyzed by Kinoshita et al. who measured the level of AFP-L3 in the pediatric 
HB and GCT patients [58]. They found the level of AFP-L3 fraction accurately assessed the malignant 
potential of the tumors evaluated and underscored the AFP-L3 fraction to be a useful marker, 
especially in infants suspected of harboring a hepatic or GCT malignancy. 
Lastly, HB can also be associated with the inappropriate secretion of peptide hormones and other 
associated proteins. Marked thrombocytosis secondary to release of tumor-derived factors with 
thrombopoietin-like activity, growth factors, platelet-derived microparticles, factors released from 
bone marrow endothelial cells, and growth factors secreted by megakaryocytes can influence this 
process [59–61]. Likewise, ectopic βHCG production can cause precocious puberty in boys (virilizing 
HB) or a forme fruste in females [62]. A case of hormonally active HB causing both ectopic ACTH 
syndrome and PTH-related peptide-induced hypercalcemia has also been reported [63]. Although these Int. J. Mol. Sci. 2012, 13 1134 
 
 
paraneoplastic syndromes are not frequently linked to HB, they underscore the importance of 
considering these oncofetal proteins as tumor-associated rather than tumor-specific, and the diverse 
presentations that can pose diagnostic and therapeutic challenges in HB. 
4.3. Lymphoma 
Lymphomas are the third most common type of primary malignancy after leukemias and brain 
cancer. Extranodal lymphomas can be non-Hodgkin lymphomas (NHL) or Hodgkin lymphomas, and 
frequently involve structures in the abdomen and pelvis, including both the solid organs (liver, spleen, 
kidneys, and pancreas) and the hollow organs of the gastrointestinal tract. The most common 
lymphomas presenting within the abdomen are NHL, primarily representing Burkitt, Burkitt-like, or 
large B-cell lymphoma. In general, these are heterogeneous tumors with different
 patterns of clinical 
behavior and response to chemotherapy [64]. Many prognostic factors have been described in 
aggressive NHL: B symptoms (fever, night sweats, weight loss), performance status,
 age, serum LDH 
level, serum β2 microglobulin (β2M), tumor bulk, and number of nodal and extranodal
  sites of   
disease [65,66]. The localization of the tumor, its clinical appearance, its features on ultrasound and 
CT scans, as well as the absence of apparent regional node involvement are indicative of a neoplasm of 
mesenchymal origin. An accurate diagnosis may require an experienced pathologist to differentiate 
soft tissue lymphoma from neoplasms such as round cell sarcoma, undifferentiated carcinomas, and 
various myxoid spindle cell sarcomas. The following subsections review β2M, CA125, and Nm23-H1 
as serum markers for extranodal lymphomas. 
4.3.1. β2 Microglobulin (β2M) 
β2M, a nonglycosylated protein of molecular mass 11,800 Da, is synthesized by all nucleated cells 
and forms a small invariable light-chain moiety of the human leukocyte antigen (HLA) (-A, -B, -C) 
through noncovalent linkage on cell surfaces. While playing a role in antigen presentation and 
regulating tumor immunity, β2M protein is present at low levels in the serum, urine, and other body 
fluids under normal physiological conditions and is almost exclusively catabolized within the kidney. 
Many studies have demonstrated that the serum or urine β2M concentration increases in various 
malignancies such as breast cancer, prostate cancer, lung cancer, renal cancer, gastrointestinal and 
nasopharyngeal cancers, multiple myeloma, and especially lymphocytic malignancies such as NHL 
and multiple myeloma [67–73]. In these malignancies, the β2M level serves as an independent and 
significant prognostic factor. More specifically, the question of clinical utility of circulating levels of 
β2M in children with lymphomas has been addressed by Bien and Balcerska [74]. Serum soluble 
interleukin (IL)-2 receptor (sIL-2Ra), β2M, LDH and erythrocyte sedimentation rate (ESR) were 
followed as markers of diagnosis, prognosis and monitoring of response to therapy in childhood 
Hodgkin’s lymphoma. The levels and rates of elevated markers reflected well for diagnostics and 
especially for monitoring of response to therapy. The markers were also shown to be increased in 
subgroups of patients with unfavorable clinical features–bulky disease (increased sIL-2Ra, ESR and 
LDH), presence of B symptoms (increased sIL-2Ra, ESR and β2M) and higher stages of disease 
(elevated sIL-2Ra and LDH). Others have advocated the routine use of serum β2M be used in Int. J. Mol. Sci. 2012, 13 1135 
 
 
association with the International Prognostic Index to define prognostic subgroups in diffuse large  
B-cell lymphoma patients [75]. 
4.3.2. CA125 
CA125 is an antigen expressed on a 220 kDa glycoprotein produced by cells derived from coelomic 
epithelium (i.e., peritoneum, pleura, and pericardium), epithelium of the female genital tract, mucosal 
cells of the stomach and colon, and mesothelial cells of serous membranes. Elevated serum 
concentrations of CA125 were thought occur only in individuals with ovarian carcinoma [76], but are 
now known to occur in many individuals with benign and neoplastic conditions such as cervical and 
endometrial carcinoma, benign and malignant ascites, kidney cancer, non–small cell lung cancer, breast 
cancer, gastric cancer, lymphoma, pelvic inflammatory disorder as well as during pregnancy [77–85]. 
Serum CA125 levels are high in patients
 with NHL, especially those with advanced disease [86]. 
Peritoneal mesothelial cells stimulated by the lymphokines
 produced by lymphoma cells are likely 
responsible
 for the high serum levels of CA125 [87,88]. Despite the enthusiasm with CA125 as a 
prognostic marker for NHL, the clinical utility surrounding the marker remains uncertain. A systematic 
review conducted by Ojha and coworkers [89] evaluated the concordance of conclusions derived from 
analyses of CA-125 as an independent marker for advanced stage and mortality within the same study 
to determine the prognostic value of CA-125 in NHL. The results derived from analyses of CA-125 as 
a marker for NHL are generally concordant. However, they noted a pervasive analytic misconception 
in previous studies precludes inferences regarding the prognostic value of CA-125. 
4.3.3. Nm23-H1 
Nm23-H1 was originally identified as a protein that has lower expression in metastatic cancer cells 
than in normal cells [90]. Nm23 proteins participate in a broad spectrum of cellular responses such  
as development, differentiation, proliferation, oncogenesis, and tumor metastasis. The mechanisms 
responsible for these pleomorphic effects are varied, as it is hypothesized that Nm23 plays a   
tissue-specific role, given its different regulatory mechanisms in various tumors. For example, reduced 
Nm23 gene expression is significantly associated with aggressive behavior in melanoma, breast, colon, 
and other carcinomas [91]. In contrast, Nm23 gene expression is high in the advanced stage of thyroid 
carcinomas and associated with a significant decrease in survival rates for patients with NB [92]. In 
hematological malignancies, NM23 genes are over expressed in acute myelogenous leukemia (AML), 
acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia in blastic crisis (CMLBC), and 
myelodysplastic syndrome (MDS). Patients with aggressive lymphomas have significantly higher 
serum nm23-H1 levels than healthy controls do, and elevated nm23-H1 levels are associated with poor 
prognosis [93]. Niitsu and coworkers found that nm23-H1 expression levels in the serum and 
cytoplasm were significant prognostic factors in diffuse large B-cell lymphoma (DLBCL) [94] and 
Hodgkin lymphomas [95]. This group has also demonstrated the clinical significance of nm23-H1 in 
NHL [96]. These results support that serum levels of nm23-H1 may be a valuable biomarker in the 
diagnosis of extranodal lymphoma. 
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4.4. Neuroblastoma (NB) 
NB accounts for 8% to 10% of all childhood cancers and is the most common extracranial pediatric 
solid tumor. This tumor remains a clinical enigma, with rates ranging from more than 90% in patients 
with locoregional tumors receiving little to no cytotoxic therapy to under 30% for those 18 months or 
older at diagnosis with metastatic disease despite receiving aggressive multimodality therapy. Age, 
stage, and amplification of the MYCN oncogene are the most validated prognostic markers. NB is 
designated as a neuroendocrine-related tumor because of the secretion of various regulatory peptides. 
The released proteins are localized in secretory granules (core- or membrane-related) in the cytosol or 
the cellular membrane. Proteins commonly associated with NB include secretory granule proteins 
chromogranin A (CgA) and synaptophysin and the cytosolic enzyme neuron-specific enolase   
(NSE) [97–100]. Other NB secretory proteins include neural-specific protein gene product 9.5, 
neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), gastrin-releasing peptide, galanin, 
somatostatin, pancreastatin, proenkephalin-derived peptides (Met-enkephalin), peptide histidine isoleucine, 
pituitary adenylate cyclase–activating peptide, atrial natriuretic factor, and midkine [101–113]. The 
spectrum of released NB-related proteins is diverse and underscores the biological complexity 
involved in the regulation and modulation of this childhood tumor. Because elevated levels of serum 
catecholamines, CgA and NSE are important markers for NB diagnosis and prediction, we review 
these markers in the following subsections. 
4.4.1. Catecholamines 
Pheochromocytoma (PCC) and NB are distinct chromaffin cell-derived tumors whose biochemical 
diagnoses depend on the secretion of one or several catecholamines. The plasma catecholamines 
dopamine (DA) and norepinephrine and their metabolites in urine, such as homovanillic acid (HVA) 
and vanillylmandelic acid (VMA), are diagnostic in both PCC and NB and have been used in clinical 
diagnosis and for early detection in screening programs in NB [114–118]. NB tumors may be 
differentiated on the basis of the biochemical markers released into the urine, as urinary catecholamine 
pattern may play different prognostic and diagnostic roles. For example, many biological parameters 
have been proposed to identify high-risk and low-risk NB, including a low VMA/HVA ratio, which is 
associated with unfavorable prognosis. Strenger et al. [119] evaluated the diagnostic and prognostic 
role of urinary catecholamines in relation to stage, age at diagnosis, and biological characteristics in 
114 NB patients. His group demonstrated that low values of urinary VMA and of VMA/HVA ratios, or 
high values of DA/VMA and of DA/HVA ratios, may be predictive of poor prognosis in aggressive 
NB, being associated with MYCN amplification, 1p deletion, and other unfavorable characteristics.  
4.4.2. Chromogranin A (CgA) and Neuron-Specific Enolase (NSE) 
Both CgA and NSE are both well established intracellular neuronal markers used to monitor NB 
disease activity and treatment response. Human CgA, a 48-kDa protein encompassing 439 amino acids, 
is an acidic glycoprotein belonging to a family of regulated secretory proteins stored in the dense core 
granules of the adrenal medulla and of many other neuroendocrine cells and neurons. NSE is the 
neuron-specific isomer of the glycolytic enzyme 2-phospho-D-glycerate hydrolyase or enolase. Int. J. Mol. Sci. 2012, 13 1137 
 
 
However, as the clinical value of serum CgA and NSE are well established for neuroendocrine tumors 
(NETs) [120,121], the elevation of these markers can also be observed in a number of other tumor 
types [122–124] and benign diseases [125–129] and therefore, do not appear as neuron-specific as 
considered previously.  
As noted, a number of serum markers have been associated with NB in an effort to improve the 
clinical outcomes by facilitating the diagnosis, prognosis, or disease monitoring. In order to identify 
the most useful tumor markers for clinical management, Riley and colleagues [130] conducted a 
systematic review, and where possible meta-analyses, of molecular and biological tumor markers for 
NB, and attempted to establish an evidence-based perspective on their clinical value for the screening, 
diagnosis, prognosis, and monitoring of patients. The genetic and biologic markers identified as 
potentially important prognostic tools included MYCN, chromosome 1p, DNA index, VMA/HVA, 
CD44, Trk-A, NSE, LDH, ferritin, and multidrug resistance. In particular, their analyses also 
underscored general problems across primary tumor marker studies, in particular poor statistical and 
heterogeneous reporting. They emphasized better clinical interpretation and more appropriate 
evidence-based reviews in the future of NB biomarkers should be sought through the cooperation of cancer 
research groups, using multiple laboratories and standardizing methods of analysis and reporting.  
4.5. Wilms Tumor (WT or Nephroblastoma) 
Nephroblastoma is the most common primary malignant renal neoplasm in childhood, representing 
6%–8% of childhood malignancies. During the last 40 years, therapeutic outcomes for WT have 
improved owing to large-scale multicentric and multidisciplinary efforts such as those by the National 
Wilms’ Tumor Study Group (currently the Renal Tumor Committee of the Children's Oncology Group) 
from North America and the International Society of Pediatric Oncology from Europe. These studies 
have served as a role model for establishing similar trials for other pediatric tumors. Current therapy 
options such as surgery, chemotherapy, and radiotherapy have led to an overall cure rate of 
approximately 85% for patients with WT. However, relapse occurs in approximately 15% of patients 
with favorable-histology WT and 50% those with anaplastic WT. Relapse occurs most commonly 
within 2 years of diagnosis and the most frequent sites are lung/pleura, tumor bed, and liver. Several 
studies in genetics and molecular biology have improved our understanding of this malignancy, and it is 
clear that a host of tumor markers such as NSE, hyaluronic acid, carcinoembryonic antigen (CEA), AFP, 
and even paraneoplastic syndromes that are attributable to the hormonal secretion of erythropoietin and 
renin are produced in WT [131]. Nevertheless, limited use of these serum markers prohibits 
widespread clinical applications in routine workup, detection of disease recurrence, or monitoring 
therapy for WT. The role of growth-related polypeptides for WT is detailed in the following section. 
4.5.1. Growth Factors, Cell Adhesion Molecules, and Extracellular Matrix Proteins 
The associations of various growth factors, cell adhesion, and extracellular matrix proteins are 
valuable prognostic markers in WT [132]. In addition to these recognized factors, angiogenetic 
regulation plays an important role in the formation of new blood vessels involved in the growth and 
metastatic spread of solid tumors, but the clinical significance of using serum levels of angiogenic 
growth factors in WT remains to be understood. This concept has been tested, and, in theory, supports Int. J. Mol. Sci. 2012, 13 1138 
 
 
that angiogenesis regulators such as basic fibroblast growth factor (bFGF), vascular endothelial growth 
factor (VEGF), and hepatocyte growth factor (HGF) may be of clinical value in WT [133]. However, 
despite the arsenal of circulating plasma proteins associated with WT, these markers have not been 
routinely used. One possible reason for these blood markers being undervalued is the inconsistencies in 
using serum or plasma and standardized methods of collecting blood samples. For instance, VEGF is 
an important angiogenic stimulatory peptide essential for solid tumor growth in WT. In a review of 
studies on the presence of VEGF in peripheral blood, Hormbrey et al. [134] found that there were 
inconsistencies among studies with regard to the sample collection method, processing, software 
manipulation and data interpretation, and the specimen (plasma, serum, or whole blood) that provides 
the best prognostic information. Although quality-control studies are required to fully define the use of 
various peptides associated with WT, the discrepancies associated with tumor markers in serum or 
plasma may contribute to the underuse of WT-secreted proteins in the clinical setting. To date, markers 
identified as yet have failed to provide consistent predictive information regarding the clinical outcome 
of WT.  
4.6. Soft Tissue Sarcomas 
Pediatric soft tissue sarcomas are relatively rare, with 850–900 children and adolescents being 
diagnosed each year with rhabdomyosarcoma (RMS) or non-RMS soft tissue sarcomas (NRSTS). 
RMS is the most common soft tissue sarcoma in children 14 years old or younger (350 cases annually), 
whereas NRSTS is more predominant in adolescents and young adults. Infants also get NRSTS, but 
their tumors make up a distinctive set of histologies, including infantile fibrosarcoma and malignant 
hemangiopericytoma, which is not seen in adolescents. 
RMS is a heterogenous tumor with 2 main histologic subtypes: embryonal (with botryoid and 
spindle cell variants) and alveolar. Approximately 60% of all newly diagnosed RMS are of embryonal 
histology. This subtype usually arises in mucosa-lined structures of the nasopharynx, auditory canal, 
and genitourinary and gastrointestinal tracts. Sarcoma botryoides, the polypoid variant of the embryonal 
subtype, typically arises in hollow organs and has a cluster-of-grapes appearance on pathologic 
inspection and imaging. Alveolar histology is seen in 20% of cases of RMS, which most commonly 
occurs in the trunk and extremities; the remainder have undifferentiated or pleomorphic histology [135]. 
Intraabdominal and pelvic RMS in children usually arises from the genitourinary system and biliary 
tree. Twenty percent of all cases of RMS in children involve the bladder, prostate, vagina, cervix, or 
paratesticular tissues and less commonly the uterus, ovary, fallopian tube, and kidney.  
In contrast, a wide variety of histologic tumor types is grouped under the umbrella term NRSTS. 
These correspond to the various normal cell types that develop from mesenchymal cells, and, as a 
result, arise in a myriad of primary sites. The most common site is the extremities, followed by the 
trunk and abdominal regions, the thorax, and the head and neck. Surgery is a major therapeutic 
modality for all pediatric soft tissue sarcomas, and radiation can play a role in the local therapy for 
these tumors. RMS is always treated with adjuvant chemotherapy, whereas chemotherapy is reserved 
for high-grade or unresectable NRSTS. Although the goal of cure is realistic for the majority of patients 
with localized tumors, the outcome for patients who present with metastatic disease remains poor.  Int. J. Mol. Sci. 2012, 13 1139 
 
 
Sarcomas have traditionally been classified according to their morphology and type of tissue they 
resemble. A growing number of molecular genetic changes have been described in sarcomas, resulting 
in accurate categorization of these soft tissue tumors. In general, these tumors can be divided into those 
showing specific genetic alterations (e.g., translocations, amplifications, or activating/inactivating 
mutations) and those displaying multiple, complex karyotypic abnormalities with no specific pattern. 
In striking contrast to the added level of genetic characterization that has strengthened conventional 
diagnostic and management approaches for some soft tissue tumors, the role of serologic markers  
in sarcomas remains to be characterized. Thus far, circulating clinical markers reported include   
NSE [136,137], polysialylated neural cell adhesion molecule (PS-NCAM) [138], creatine kinase   
MB [139,140], midkine [141], osteopontin [142], and CA125 [143] for some sarcomas, but no routine 
serum biomarker has had efficient clinical application yet. As further efforts are required to establish 
the clinical role of serologic tests in this malignancy, the identification of unique serum signatures for 
pediatric soft tissue sarcomas may provide significant value to diagnosis, accurate prognostic 
prediction, and evaluation of disease and treatment progression beyond the current standard of care. 
5. Conclusions  
Serum biomarkers are useful tools to differentiate solid tumors in children. There is an abundance 
of literature on serum biomarkers, but this review has focused on a select handful of clinically relevant 
markers used for the detection, surveillance, and survival prediction of common pediatric malignancies 
of the chest and abdomen. Although these laboratory tests are helpful in discriminating masses, it must 
be recognized that some markers do not always accurately indicate disease, but are in general reliable 
when used in combination with other diagnostic tools. They can be used to obtain information required 
for planning future cancer treatment. 
Nevertheless, professional societies have formal practice guidelines for the use of most tumor 
markers based on evidence-justified practice, which culminates pertinent, trustworthy information by 
systematically acquiring, analyzing, and transferring research findings into clinical, management, and 
policy arenas [144]. For instance, a wealth of publications on GCTs serum markers supports the use of 
hCG, AFP, and LDH serum concentrations for clinical management. Recent reviews by the American 
Society of Clinical Oncology and the National Academy of Clinical Biochemistry have outlined 
updated practice guidelines in adults [145,146]. These studies underscore the relevant issue of 
comparing age-related variation in laboratory values. Although most studies on existing GCTs tumor 
markers in children have similar observations, there are considerable differences in tumor biology in 
children and the extrapolation of results from studies in adults to children is controversial. For example, 
40%–55% of GCTs in children are found at extragonadal locations as against the 5%–10% of GCTs 
found in adults at the same location [147–149]. This difference is likely due to variations in the 
maturity of the germ cells that give rise to the tumors in these age groups [150]. GCTs in children 
likely originate from a primordial germ cell (PGC) that underwent immediate reprogramming to 
become a pluripotent embryonic germ cell, whereas GCTs in adolescents and young adults most likely 
originate from more mature PGCs, which may be unable to survive outside of the normal niches of the 
ovary and testis or specialized sites such as the thymus in the case of mediastinal GCTs [151]. 
Additionally, the absence of BRAF mutations in pediatric GCTs in comparison to adult tumors was Int. J. Mol. Sci. 2012, 13 1140 
 
 
recently reported and further supports evidence for patient age-related biological differences [152]. 
This translates to distinct clinical/genetic profiles for pediatric and adult GCTs, and, especially in cases 
of AFP wherein these serum levels are developmentally regulated, highlights the significant role of the 
age of patients in determining normal baseline serum levels of some tumor markers.  
Although age-adapted reference intervals are a prerequisite for proper interpretation of laboratory 
data, other sources of laboratory testing variation include preanalytical, total random analytical error, 
and intraindividual normal biology. The discrimination of different molecular forms of tumor markers 
may also have ramifications at the clinical level. For example, some question the validity of 
differences in hCG concentrations, as the recognition of hCG variants [nonnicked and nicked intact 
hCG (hCG and hCGn), nonnicked and nicked free β-subunit (hCGβ and hCGnβ), and regular and 
hyperglycosylated (or large) free hCGα] can cause discordance in hCG immunoassay results. Cao and 
Rej identified the following factors that contribute to the incorrect reporting of hCG results by 
laboratories: (a) complexity of the hCG molecule and confusion of nomenclature among various forms 
of hCG; (b) laboratory personnel’s lack of awareness of the distinctions in the forms of hCG and 
failure to recognize the specificity of assays for measurement of different forms; (c) lack of clarity and 
uniformity in manufacturers’ reagent labeling; and (d) lack of information on the specificity of each 
method for the various forms of hCG in most product inserts [153]. 
It is vital to accurately detect the specific hCG-related molecule in patients with malignant disease. 
Immunochemical characterization has shown that though intact hCG is abundantly produced by the 
placenta and germ cell tumors, it is the serum free β-hCG subunit (independent of the common 
glycoprotein hormone α subunit [GPHα]) that is also a tumor marker in many non-trophoblastic tumors, 
which include common epithelial cancers. Therefore, it is critical to know which hCG isoforms are 
measured in order to avoid false-positive results, as most automated commercial laboratory tests, 
point-of-care tests, and over-the-counter tests are limited in what they detect, as they focus only on 
regular hCG. 
Despite considerable potential limitations to current pediatric tumor markers, continued progress in 
tumor marker discovery will likely come from rigorous translational investigations that will integrate 
multidimensional analyses from various emerging technologies to deliver more specific predictive and 
prognostic markers. Undoubtedly, next-generation biomarkers will likely stem from the growing omics 
technologies, which will amalgamate large-scale genomics, transcriptomics, and proteomics to 
promote personalized cancer care. Consequently, proteomics based biomarker discovery is one of the 
omics platforms that has garnered much interest in many diseases, including cancer. The enthusiasm 
towards cancer-related proteomics applications is due to the role proteomics can provide in bridging 
the gap between genetic alterations underlying cancer and cellular physiology, such that a cell’s 
genome is relatively stable and gives information of the organism’s gene expression while the 
proteome is dynamic, complex and variable. Moreover, there is a growing opinion in favor of the role 
of targeting proteomic measurements for improving blood-based human diagnostics [154,155]. Blood 
has been the logical biomarker source, as blood equilibrates with tissues and generally harbors proteins 
that may be identified to yield a specific proteome pattern related to a distinct pathologic process 
occurring in the body. To date, blood-based proteomic biomarker efforts have had little success, in 
large part because the relatively small number of highly abundant proteins make the reliable detection 
of low abundant disease-related proteins challenging due to the wide dynamic range of concentrations Int. J. Mol. Sci. 2012, 13 1141 
 
 
of proteins in a blood sample. Given the substantial complexity of plasma and the vast dynamic range 
of protein abundance, approaches used to simplify and increase the depth of proteomic analysis include 
fractionation strategies, targeted protein subpopulation enrichment (phosphoproteins, glycoproteins, 
etc.), and differential quantifying protein methods such as isobaric tags for relative and absolute 
quantification (iTRAQ). 
In addition, other novel work in biomarker discovery involves proximal fluid proteomics. Proximal 
fluid, the fluid derived from the extracellular milieu of tissues, contains a large repertoire of shed and 
secreted proteins that are likely to be present at higher concentrations than in the plasma or serum. It 
has been hypothesized that many, if not all, proximal fluid proteins exchange with peripheral 
circulation, which has triggered the use of proximal fluids as a primary sample source for protein 
biomarker discovery [156]. 
Lastly, exciting opportunities in nanoscale exploration open new strategies for serum protein 
analysis. For example, Pujia and colleagues recently described a tool based on biodegradable 
nanoporous nanoparticles (NPNPs) that allows the harvesting of low-molecular-weight fractions of 
crude human serum or plasma [157]. NPNPs with a diameter of 200 nm and pore size of a few 
nanometers have been obtained by ultrasonication of nanoporous silicon. When incubated with a 
solution, NPNPs harvest only molecules that are small enough to be absorbed into the nanopores. 
These molecules can then be recovered by centrifugation and dissolved in water to give samples for 
further analyses. The development and use of novel methods in serum biomarker discovery may 
include strategies that use nanostructured materials and other high-throughput methods such as protein 
arrays, multiplexed protein assays, and chip-based proteomic platforms. For instance, utilizing   
protein-chip based array proteomic technologies, Wang et al. [158] performed protein profiling of 
serum samples from pre-surgery and post-surgery patients with WT and healthy controls. Two peaks 
(11,526 and 4,756 Da) showing significant differential expression not only between pre-surgery and 
control sera but also between pre-surgery and post-surgery sera were identified and characterized as 
serum amyloid A1 (SAA1) and apolipoprotein C-III (APO C-III). 
In the continued search for ideal tumor markers in children, it is essential to pursue study designs 
that are appropriately powered and lend themselves to independent replication. There are several 
criteria for any biomarker to be considered clinically relevant. Sturgeon and colleagues recently 
updated the National Academy of Clinical Biochemistry laboratory medicine practice guidelines and 
quality requirements for the use of tumor markers. The most important feature with regard to these 
biomarkers is the ability to affect patient management [146]. Savage and Everett have defined the 
other challenges that are faced in biomarker research in children [159]. In particular, an important issue 
with regard to proteomics is the validation of promising candidates for pediatric diseases by blood-
based profiling [160]. Proteomic profiling on children has been criticized as limited sample sizes and 
volumes are available for analysis, which may reduce the accuracy of the validation. Also, markers in 
children are discovered in the context of growth and development; few studies have reported serum or 
plasma proteins from healthy children. It is important to obtain serum or plasma profiles to determine 
age-related changes in order to better comprehend whether candidate proteins are related to disease  
or to normal growth. Currently, multiple profiling projects on the human plasma proteome are   
underway [161–163], and recent study has reported a web-based database of human plasma proteins 
from normal individuals [164]. Such a resource specific to children needs to be established to enable Int. J. Mol. Sci. 2012, 13 1142 
 
 
proper comparisons to interpret blood samples from healthy children and cancer patients in order to 
drive the identification and validation of biomarker targets. 
The progress toward early diagnosis, curative therapy, and favorable outcomes in childhood solid 
cancer patients and survivors depends not only on developing continued strategies to identify biomarkers 
for more precise diagnosis, targeted therapy, and possibly prevention, but also designating additional 
funding or redistributing existing resources for furthering the study of childhood malignancies that 
continue to have static or poor survival trends. For example, 5-year survival rates for pediatric and 
adolescent sarcomas (Ewing, osteosarcoma, and rhabdomyosarcoma) have not drastically changed 
over the past 2 decades as compared with those for other solid tumors such as non–central nervous 
system GCTs and Wilms tumor [2]. Given the paucity of data on biomarkers and the challenging 
clinical management of children with metastatic sarcomas, a cross-disciplinary biological approach 
that comprehensively assesses DNA, RNA, protein, and metabolites to identify molecular drivers and 
markers is warranted to conduct small, short, and more economical individualized clinical trials. We 
foresee molecular data on solid pediatric cancers being translated into practical diagnostic and 
treatment modalities in order to optimize the success rate and hasten the implementation of effective 
therapies into the clinic. 
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